Drug Details
General Information of the Drug (ID: DR3046) | ||||
---|---|---|---|---|
Name |
Raltitrexed
|
|||
Synonyms |
Raltitrexed; Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ICI D1694; UNII-FCB9EGG971; D1694; CHEBI:5847; C21H22N4O6S; Raltitrexed (Tomudex); ZD-16; FCB9EGG971; ZD 1694; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_CID_26482; DSSTox_RID_81653; DSSTox_GSID_46482; (S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)-methyl)amino)thiophene-2-carboxamido)pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; (2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; D16; Tomudex (TN); D 1694; CAS-112887-68-0; Raltitrexed (JAN/USAN/INN); (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 1hvy; 2kce; 2tsr; ZN-D1694; KS-5069; ZD1694; Raltitrexed; SCHEMBL7438; MLS001424225; MLS006010125; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; Raltitrexed [USAN:INN:BAN]; GTPL7403; DTXSID0046482; BDBM18795; QCR-125; 1i00; HMS2052I03; HMS3715P08; AMY42113; ZINC3832372; Tox21_112237; BDBM50027655; MFCD00864168; NSC639186; s1192; AKOS015894877; AKOS015994729; Tox21_112237_1; CCG-101075; CCG-221273; DB00293; NC00325; NCGC00263534-02; HY-10821; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-; NCI60_013008; SMR000469217; SMR002529608; BCP0726000267; SW197705-2; C11372; D01064; S-7682; AB00698356-05; 134189-EP2275102A1; 134189-EP2292233A2; 887R680; SR-01000763351; J-524216; SR-01000763351-3; BRD-K89839824-001-01-2; Q15304877; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; N-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)carbonyl]-L-glutamic acid; N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Rectum cancer [ICD-11: 2B92] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C21H22N4O6S
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1
|
|||
InChI |
1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
|
|||
InChIKey |
IVTVGDXNLFLDRM-HNNXBMFYSA-N
|
|||
CAS Number |
CAS 112887-68-0
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Fluoroorotic acid | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Candida thymidylate synthase (Candi TMP1) | Molecule Info | [3] | |
BioCyc | Pyrimidine deoxyribonucleotides biosynthesis from CTP | Click to Show/Hide | ||
2 | Pyrimidine deoxyribonucleotides de novo biosynthesis | |||
3 | Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||
4 | Superpathway of pyrimidine deoxyribonucleoside salvage | |||
5 | DTMP de novo biosynthesis (mitochondrial) | |||
6 | Pyrimidine deoxyribonucleosides salvage | |||
KEGG Pathway | Pyrimidine metabolism | Click to Show/Hide | ||
2 | One carbon pool by folate | |||
3 | Metabolic pathways | |||
Panther Pathway | De novo pyrimidine deoxyribonucleotide biosynthesis | Click to Show/Hide | ||
2 | Formyltetrahydroformate biosynthesis | |||
Pathwhiz Pathway | Pyrimidine Metabolism | Click to Show/Hide | ||
Pathway Interaction Database | E2F transcription factor network | Click to Show/Hide | ||
Reactome | E2F mediated regulation of DNA replication | Click to Show/Hide | ||
2 | Pyrimidine biosynthesis | |||
3 | G1/S-Specific Transcription | |||
WikiPathways | Trans-sulfuration and one carbon metabolism | Click to Show/Hide | ||
2 | Retinoblastoma (RB) in Cancer | |||
3 | One Carbon Metabolism | |||
4 | Integrated Pancreatic Cancer Pathway | |||
5 | miR-targeted genes in muscle cell - TarBase | |||
6 | miR-targeted genes in lymphocytes - TarBase | |||
7 | miR-targeted genes in leukocytes - TarBase | |||
8 | miR-targeted genes in epithelium - TarBase | |||
9 | Metabolism of nucleotides | |||
10 | Fluoropyrimidine Activity |